Abstract
Corynebacterium parvum, an anaerobic diotheroid, has been demonstrated to be therapeutic in several tumor models by stimulating immunologic defenses. Formalin-killed C. parvum was investigated in the present study as an immunotherapeutic agent in the treatment of murine ovarian cancer, a model that closely simulates the activity of clinical disease. C. parvum successfully prolonged survival in murine ovarian cancer and its effectiveness improved with increasing dosage. The efficacy of C. parvum was further enhanced by a multiple-dose regimen. A previous report demonstrated the efficacy of heterologous tumor antisera in the serologic treatment of murine ovarian cancer. At the dosages investigated, the combination of C. parvum and heterologous tumor antisera (SG-200) provided longer survival than either modality independently. C. parvum is an effective anti-cancer agent in murine ovarian cancer and may find utility in a clinical setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
